ESSA Pharma, Inc.

ESSA Pharma, Inc. is a clinical-stage pharmaceutical company dedicated to developing innovative treatments for prostate cancer, focusing on advanced therapies that target androgen receptor signaling. Founded in 2009 and headquartered in Vancouver, Canada, ESSA Pharma specializes in therapies for prostate cancer. The company is led by CEO David Parkinson.

ESSA has secured multiple funding rounds, with the most recent being a PIPE round in August 2020, bringing in USD 49. 00 mn from several investors including Pfizer Inc. and Ridgeback Capital Management. ESSA Pharma is focused on developing masofaniten (previously EPI-7386), an investigational first-in-class N-terminal domain androgen receptor inhibitor aimed at patients with castration-resistant prostate cancer (CRPC).

The therapy disrupts the androgen receptor signaling pathway and is currently in clinical trials across the United States and Canada, targeting men diagnosed with advanced prostate cancer. ESSA Pharma's revenue model is primarily based on partnerships and potential licensing agreements that result from successful clinical trials. Collaborations with healthcare providers and oncology specialists during the trial phases foster relationships that may lead to commercialization opportunities once regulatory approvals are obtained. Specific pricing details for masofaniten have not been disclosed.

ESSA Pharma intends to leverage the USD 49. 00 mn raised in August 2020 to further advance the clinical development of masofaniten and explore potential new product offerings in the prostate cancer space. The company is focusing on expanding its clinical trials and market reach, particularly in North America, to facilitate effective treatment options for advanced prostate cancer patients. As the research progresses, ESSA aims to establish strategic partnerships that could enhance its market presence and product pipeline.